The goal of this project is to examine the cardiac symptoms and physiologic changes after administration of a reduced dose of carbetocin in participants undergoing elective cesarian section. * Does reduced dose carbetocin (50mcg) have fewer cardiac side effects than usual dose carbetocin (100mcg) when comparing patient reported symptoms, ECG changes and troponin increases? * Is there a relationship between patient reported cardiac symptoms after carbetocin administration and subjective measures of cardiac ischemia (ECG changes and troponin increases? Researchers will compare 50mcg of carbetocin to the control group of 100mcg of carbetocin in patients undergoing elective cesarian section. Participants will: * Be given 50mcg or 100mcg of carbetocin during cesarian section * Asked to report cardiac symptoms * Be assessed for ECG changes and blood loss using standard of practice monitoring * Have a troponin I blood test completed after delivery
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
200
A uterotonic agent used for the prevention of postpartum hemorrhage in Cesarian section
Kingston Health Sciences Centre
Kingston, Ontario, Canada
Patient reported symptoms
Subjective patient reported symptoms of cardiac ischemia, reported with descriptive words
Time frame: within 5 minutes of study drug administration
Troponin I levels
Troponin I levels on blood work
Time frame: One day after study drug administration
ECG: ST segment
Changes to the ST segment on ECG
Time frame: 5 minutes after study drug administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.